An excisional biopsy is performed and the diagnosis of superficial spreading melanoma is confirmed. The lesion is 1.1 mm thick. Which of the following is the most appropriate next step in management?

Surgical excision with 1-2 cm safety margins and sentinel lymph node study

Surgical excision with 0.5-1 cm safety margins only

Surgical excision with 1 cm safety margins only

Surgical excision with 1-2 cm safety margins only

Surgical excision with 0.5-1 cm safety margins and sentinel lymph node study

A 57-year-old woman with non-small cell lung cancer comes to the physician 4 weeks after her tumor was resected. She takes no medications. The physician starts her on a treatment regimen that includes vinblastine. This treatment puts the patient at highest risk for which of the following?

Progressive multifocal leukoencephalopathy

Patient 1 – A 26-year-old woman presents to her primary care physician for an annual exam. She currently does not have any acute concerns and says her health has been generally well. Medical history is significant for asthma, which is managed with an albuterol inhaler. Her last pap smear was unremarkable. She is currently sexually active with one male and consistently uses condoms. She occasionally smokes marijuana and drinks wine once per week. Her mother recently passed away from advanced ovarian cancer. Her sister is 37-years-old and was recently diagnosed with breast cancer and ovarian cancer. Physical examination is remarkable for a mildly anxious woman. Patient 2 – A 27-year-old woman presents to her primary care physician for an annual exam. She says that she would like to be screened for breast cancer since two of her close friends were recently diagnosed. She noticed she has a small and mobile mass on her left breast, which increases in size and becomes tender around her time of menses. Family history is remarkable for hypertension in the father. The physical exam is significant for a small, well-defined, and mobile mass on her left breast that is not tender to palpation. Which of the following is the best next step in management for patient 1 and 2?

Patient 1 – BRCA testing. Patient 2 – Breast ultrasound

Patient 1 – Breast ultrasound. Patient 2 – Return in 3 months for a clinical breast exam

Patient 1 – Reassurance. Patient 2 – Breast ultrasound

Patient 1 – CA-125 testing. Patient 2 – BRCA testing

Patient 1 – Breast and ovarian ultrasound. Patient 2 – Mammography

A 50-year-old obese woman presents for a follow-up appointment regarding microcalcifications found in her left breast on a recent screening mammogram. The patient denies any recent associated symptoms. The past medical history is significant for polycystic ovarian syndrome (PCOS), for which she takes metformin. Her menarche occurred at age 11, and the patient still has regular menstrual cycles. The family history is significant for breast cancer in her mother at the age of 72. The review of systems is notable for a 6.8 kg (15 lb) weight loss in the past 2 months. The vital signs include: temperature 37.0°C (98.6°F), blood pressure 130/70 mm Hg, pulse 82/min, respiratory rate 17/min, and oxygen saturation 98% on room air. On physical examination, the patient is alert and cooperative. The breast examination reveals no palpable masses, lymphadenopathy, or evidence of skin retraction. A biopsy of the left breast is performed, and histologic examination demonstrates evidence of non-invasive malignancy. Which of the following is the most appropriate definitive treatment for this patient?

Observation with bilateral mammograms every 6 months

Neoadjuvant and adjuvant therapy timing for USMLE Step 2 CK: High-Yield Surgery Lessons

⏳ Neoadjuvant vs. Adjuvant Therapy

📌 Neoadjuvant = New (before surgery). Adjuvant = Add-on (after surgery).

Systemic or local therapy (chemo, radiation, immunotherapy) timed around the primary surgical intervention to improve cure rates.

Neoadjuvant Therapy (Before)	Adjuvant Therapy (After)
Goal: Shrink locally advanced tumors to improve resectability (downstaging).	Goal: Eradicate residual micrometastatic disease after complete resection.
Benefit: Assesses in vivo tumor response; can allow for less morbid surgery.	Benefit: Treatment is tailored based on definitive pathologic staging.
Examples: Rectal, esophageal, osteosarcoma, locally advanced breast cancer.	Examples: Colon, melanoma, non-small cell lung, most breast cancers.

Neoadjuvant and Adjuvant Therapy Timeline

Management - The Timing Game

Error generating content for this concept group: Failed to process successful response

⚖️ Complications - Treatment Trade-offs

Neoadjuvant Therapy Risks:
- ⚠️ Delay of Definitive Surgery: Risk of tumor progression or metastasis if the cancer is resistant to initial therapy.
- Pre-op Toxicity: Systemic therapy side effects (e.g., myelosuppression, cardiotoxicity, nephrotoxicity) may render a patient unfit for a major operation.
- Impaired Healing: Residual effects of therapy, especially radiation, can ↑ risk of post-op wound complications like dehiscence and infection.
- Pathologic Obscuration: Tumor downstaging can make accurate prognostic staging difficult post-resection.
Adjuvant Therapy Risks:
- ⚠️ Delay of Systemic Control: Micrometastases may proliferate during the surgical recovery period before systemic therapy begins.
- Post-op Delays: Surgical complications (e.g., anastomotic leak, infection, ileus) can postpone or prevent the initiation of necessary adjuvant therapy.
- Reduced Tolerance: Patients may be too deconditioned post-surgery to tolerate full-dose chemotherapy or radiation.

⭐ Key Trade-off: Adjuvant radiation to a fresh surgical field significantly increases the risk of long-term complications like tissue fibrosis, chronic lymphedema, and poor wound healing compared to pre-operative radiation.

⚡ Biggest Takeaways

Neoadjuvant therapy is given before surgery to downstage tumors, improving resectability and enabling less radical procedures (e.g., breast conservation).

It allows for in vivo assessment of tumor response, which can guide subsequent treatment.

Adjuvant therapy is administered after surgery to eliminate micrometastatic disease and decrease recurrence risk.

Adjuvant treatment is guided by definitive pathologic staging from the resected specimen.

Typically initiated 3-6 weeks post-op to allow for adequate patient recovery.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play